Celldex Therapeutics, Inc. (CLDX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 20M 40M 60M FY09: 15.2M FY10: 46.8M FY11: 9.3M FY12: 11.2M FY13: 4.1M FY14: 3.6M FY15: 5.5M FY16: 6.8M FY17: 12.7M FY18: 9.5M FY19: 3.6M FY20: 7.4M FY21: 4.7M FY22: 2.4M FY23: 6.9M FY24: 7M FY25: 1.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 5M 10M 15M FY16: 5.2M FY17: 12M FY18: 8.8M FY19: 3.5M FY20: 7.2M FY21: 4.6M FY22: 2.3M FY23: 6.6M FY24: 6.8M FY25: 1.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-300M -200M -100M 0 100M 200M 300M FY09: -36.9M FY10: -6.5M FY11: -43.4M FY12: -58.1M FY13: -81.4M FY14: -122.4M FY15: -129.5M FY16: -132.9M FY17: -121.5M FY18: -156.4M FY19: -55M FY20: -63.4M FY21: -71.2M FY22: -115.2M FY23: -154.5M FY24: -195.1M FY25: -287.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-270M -180M -90M 0 90M 180M 270M FY09: -36.5M FY10: -2.5M FY11: -44.8M FY12: -59.1M FY13: -81.5M FY14: -118.1M FY15: -127.2M FY16: -128.5M FY17: -93M FY18: -151.2M FY19: -50.9M FY20: -59.8M FY21: -70.5M FY22: -112.3M FY23: -141.4M FY24: -157.9M FY25: -258.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 600K 1.2M 1.8M FY16: 1.6M FY17: 700K FY18: 700K FY19: 100K FY20: 200K FY21: 100K FY22: 100K FY23: 300K FY24: 200K FY25: 200K FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-240M -160M -80M 0 80M 160M 240M FY09: -29.9M FY10: -30.4M FY11: -35.7M FY12: -49.8M FY13: -67.7M FY14: -101.5M FY15: -98.9M FY16: -113M FY17: -99.9M FY18: -75.2M FY19: -46.4M FY20: -40.4M FY21: -60.9M FY22: -103.7M FY23: -107.3M FY24: -157.8M FY25: -210.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-240M -160M -80M 0 80M 160M 240M FY09: -30.4M FY10: -32.5M FY11: -36.2M FY12: -50.1M FY13: -71.9M FY14: -103.5M FY15: -103.8M FY16: -115.8M FY17: -101.7M FY18: -76M FY19: -47.1M FY20: -42M FY21: -62.2M FY22: -105.6M FY23: -109.1M FY24: -159.7M FY25: -213.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M FY09: 19.8M FY10: 31.9M FY11: 39.5M FY19: 14.5K FY20: 29.6K FY21: 42.9K FY22: 46.9K FY23: 48.4M FY24: 64.4M FY25: 66.4M FY09 FY10 FY11 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '11: -1.14 Q1 '12: -1.10 Q2 '12: -1.06 Q3 '12: -1.04 Q4 '12: -1.02 Q1 '13: -0.98 Q2 '13: -0.99 Q3 '13: -1.03 Q4 '13: -1.03 Q1 '14: -1.13 Q2 '14: -1.21 Q3 '14: -1.23 Q4 '14: -1.32 Q1 '15: -1.32 Q2 '15: -1.33 Q3 '15: -1.34 Q4 '15: -1.31 Q1 '16: -1.33 Q2 '16: -1.32 Q3 '16: -1.29 Q4 '16: -1.26 Q1 '17: -1.19 Q2 '17: -1.10 Q3 '17: -1.01 Q4 '17: -1.13 Q1 '18: -13.46 Q2 '18: -14.90 Q3 '18: -15.36 Q4 '18: -15.75 Q1 '19: -4.54 Q2 '19: -3.71 Q3 '19: -3.80 Q4 '19: -3.63 Q1 '20: -2.96 Q2 '20: -2.62 Q3 '20: -2.23 Q4 '20: -2.14 Q1 '21: -1.83 Q2 '21: -1.67 Q3 '21: -1.76 Q4 '21: -1.64 Q4 '12 Q2 '14 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.